Patents by Inventor Steven Nye

Steven Nye has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ERK3 MAP2 protein kinase
    Patent number: 6303358
    Abstract: The present invention relates to a newly identified family of protein serine/threonine kinases which phosphorylate microtubule-associated protein 2 (MAP2). It is based, in part, on the cloning and characterization of novel MAP2 kinases designated extracellular signal-regulated kinase 1, 2, and 3 (ERK1, ERK2, ERK3) which are expressed in the central nervous system, and on the identification of another ERK family member, ERK4, with antisera. The present invention provides for recombinant nucleic acid molecules and proteins representing members of the MAP2 kinase family, and also for microorganisms, transgenic animals, and cell lines comprising recombinant MAP2 kinase molecules. In additional embodiments of the invention, the present invention provides for methods for assaying cellular factor activity, including, but not limited to, nerve growth factor activity, in which the activation of MAP2 kinase serves as an indicator of cellular factor activity.
    Type: Grant
    Filed: July 7, 1997
    Date of Patent: October 16, 2001
    Assignees: Regeneron Pharmaceuticals, Inc., University of Texas
    Inventors: Teri G. Boulton, Melanie H. Cobb, George D. Yancopoulos, Steven Nye, Nikos Panayotatos
  • ERK1 MAP2 protein kinase
    Patent number: 6297035
    Abstract: The present invention relates to a newly identified family of protein serine/threonine kinases which phosphorylate microtubule-associated protein 2 (MAP2). It is based, in part, on the cloning and characterization of novel MAP2 kinases designated extracellular signal-regulated kinase 1, 2, and 3 (ERK1, ERK2, ERK3) which are expressed in the central nervous system, and on the identification of another ERK family member, ERK4, with antisera. The present invention provides for recombinant nucleic acid molecules and proteins representing members of the MAP2 kinase family, and also for microorganisms, transgenic animals, and cell lines comprising recombinant MAP2 kinase molecules. In additional embodiments of the invention, the present invention provides for methods for assaying cellular factor activity, including, but not limited to, nerve growth factor activity, in which the activation of MAP2 kinase serves as an indicator of cellular factor activity.
    Type: Grant
    Filed: September 17, 1997
    Date of Patent: October 2, 2001
    Assignees: Regeneron Pharmaceuticals, Inc., University of Texas
    Inventors: Teri G. Boulton, Melanie H. Cobb, George D. Yancopoulos, Steven Nye, Nikos Panayotatos
  • Antibodies directed toward extracellular signal-related kinases
    Patent number: 6277963
    Abstract: The present invention relates to a newly identified family of protein serine/threonine kinases which phosphorylate microtubule-associated protein 2 (MAP2). It is based, in part, on the cloning and characterization of novel MAP2 kinases designated extracellular signal-regulated kinase 1, 2, and 3 (ERK1, ERK2, ERK3) which are expressed in the central nervous system, and on the identification of another ERK family member, ERK4, with antisera. The present invention provides for recombinant nucleic acid molecules and proteins representing members of the MAP2 kinase family, and also for microorganisms, transgenic animals, and cell lines comprising recombinant MAP2 kinase molecules. In additional embodiments of the invention, the present invention provides for methods for assaying cellular factor activity, including, but not limited to, nerve growth factor activity, in which the activation of MAP2 kinase serves as an indicator of cellular factor activity.
    Type: Grant
    Filed: September 18, 1997
    Date of Patent: August 21, 2001
    Assignees: Regeneron Pharmaceuticals, Inc., University of Texas
    Inventors: Teri G. Boulton, Melanie H. Cobb, George D. Yancopoulos, Steven Nye, Nikos Panayotatos
  • Family of MAP2 protein kinases
    Patent number: 5914261
    Abstract: The present invention relates to a newly identified family of protein serine/threonine kinases which phosphorylate microtubule-associated protein 2 (MAP2). It is based, in part, on the cloning and characterization of novel MAP2 kinases designated extracellular signal-regulated kinase 1, 2, and 3 (ERK1, ERK2, ERK3) which are expressed in the central nervous system, and on the identification of another ERK family member, ERK4, with antisera. The present invention provides for recombinant nucleic acid molecules and proteins representing members of the MAP2 kinase family, and also for microorganisms, transgenic animals, and cell lines comprising recombinant MAP2 kinase molecules. In additional embodiments of the invention, the present invention provides for methods for assaying cellular factor activity, including, but not limited to, nerve growth factor activity, in which the activation of MAP2 kinase serves as an indicator of cellular factor activity.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: June 22, 1999
    Assignees: Regeneron Pharmaceuticals, Inc., Board of Regents, University of Texas System
    Inventors: Teri G. Boulton, Melanie H. Cobb, George D. Yancopoulos, Steven Nye, Nikos Panayotatos
  • Family of MAP2 protein kinases
    Patent number: 5872006
    Abstract: The present invention relates to a newly identified family of protein serine/threonine kinases which phosphorylate microtubule-associated protein 2 (MAP2). It is based, in part, on the cloning and characterization of novel MAP2 kinases designated extracellular signal-regulated kinase 1, 2, and 3 (ERK1, ERK2, ERK3) which are expressed in the central nervous system, and on the identification of another ERK family member, ERK4, with antisera. The present invention provides for recombinant nucleic acid molecules and proteins representing members of the MAP2 kinase family, and also for microorganisms, transgenic animals, and cell lines comprising recombinant MAP2 kinase molecules. In additional embodiments of the invention, the present invention provides for methods for assaying cellular factor activity, including, but not limited to, nerve growth factor activity, in which the activation of MAP2 kinase serves as an indicator of cellular factor activity.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: February 16, 1999
    Assignees: Regeneron Pharmaceuticals, Inc., Board of Regents The University of Texas System
    Inventors: Teri G. Boulton, Melanie H. Cobb, George D. Yancopoulos, Steven Nye, Nikos Panayotatos
  • Family of MAP2 protein kinases
    Patent number: 5776751
    Abstract: The present invention relates to a newly identified family of protein serine/threonine kinases which phosphorylate microtubule-associated protein 2 (MAP2). It is based, in part, on the cloning and characterization of novel MAP2 kinases designated extracellular signal-regulated kinase 1, 2, and 3 (ERK1, ERK2, ERK3) which are expressed in the central nervous system, and on the identification of another ERK family member, ERK4, with antisera. The present invention provides for recombinant nucleic acid molecules and proteins representing members of the MAP2 kinase family, and also for microorganisms, transgenic animals, and cell lines comprising recombinant MAP2 kinase molecules. In additional embodiments of the invention, the present invention provides for methods for assaying cellular factor activity, including, but not limited to, nerve growth factor activity, in which the activation of MAP2 kinase serves as an indicator of cellular factor activity.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: July 7, 1998
    Assignees: Regeneron Pharmaceuticals, Inc., Board of Regents, Univ Of Texas
    Inventors: Teri G. Boulton, Melanie H. Cobb, George D. Yancopoulos, Steven Nye, Nikos Panayotatos
  • Family of map2 protein kinases
    Patent number: 5595904
    Abstract: The present invention relates to a newly identified family of protein serine/threonine kinases which phosphorylate microtubule-associated protein 2 (MAP2). It is based, in part, on the cloning and characterization of novel MAP2 kinases designated extracellular signal-regulated kinase 1, 2, and 3 (ERK1, ERK2, ERK3) which are expressed in the central nervous system, and on the identification of another ERK family member, ERK4, with antisera. The present invention provides for recombinant nucleic acid molecules and proteins representing members of the MAP2 kinase family, and also for microorganisms, transgenic animals, and cell lines comprising recombinant MAP2 kinase molecules. In additional embodiments of the invention, the present invention provides for methods for assaying cellular factor activity, including, but not limited to, nerve growth factor activity, in which the activation of MAP2 kinase serves as an indicator of cellular factor activity.
    Type: Grant
    Filed: January 3, 1994
    Date of Patent: January 21, 1997
    Assignees: Board of Regents, Univ. of Texas, Regeneron Pharmaceuticals, Inc.
    Inventors: Teri G. Boulton, Melanie H. Cobb, George D. Yancopoulos, Steven Nye, Nikos Panayotatos